ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
비용종 치료 시장의 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 9.5%로 81억 6,000만 달러로 성장할 전망입니다. 예측기간의 성장은 의약품 개발, 맞춤형 의료, 원격의료 서비스, 환자 중심 관리, 규제 당국의 승인에 기인할 것으로 예상됩니다. 예측기간의 주요 동향으로는 진단기술, 의료의 진보, 생물학적요법, 면역요법, 공동연구 등이 있습니다.
향후 5년간의 예측 성장률 9.5%는 과거 예측에서 0.1% 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 부과는 스위스나 한국에서 조달하는 생물학적 요법이나 내시경하 부비강 수술 기구의 비용을 상승시키고, 개입의 지연이나 이비인후과(ENT) 치료 비용의 상승을 초래하기 때문에 만성비부비강염의 치료에 지장을 초래할 가능성이 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
건강 관리 지출 증가는 비용종 치료 시장의 성장을 가속할 것으로 예측됩니다. 헬스케어 지출이란 의료 서비스, 치료, 투약, 의료 인프라와 관련된 비용을 충당하기 위해 헬스케어 시스템 내의 개인, 정부, 조직이 이용하는 총 재원을 말합니다. 건강 관리 예산이 증가함에 따라 비용종의 진단, 관리 및 치료에 할당되는 자원도 증가할 것으로 예측됩니다. 이러한 재정 투자는 첨단 치료법, 혁신적인 치료 옵션, R&D 증가에 대한 환자 접근성을 강화하고 궁극적으로 시장 개척을 촉진합니다. 예를 들어, 2023년 12월 미국 연방정부기관인 Medicare & Medicaid Service Center의 데이터에 따르면 미국의 의료비는 4.1% 증가하여 2022년에는 4조 5,000억 달러에 이르렀으며, 2021년에 기록된 3.2% 성장률을 웃도는 것으로 나타났습니다. 따라서 의료비 증가는 비용종 치료 시장의 성장을 가속하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 비용종 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 비용종 치료 시장 : 성장률 분석
세계의 비용종 치료 시장 실적 : 규모와 성장(2019-2024년)
세계의 비용종 치료 시장 예측 : 규모와 성장(2024-2029년, 2034F)
세계의 비용종 치료 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 비용종 치료 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
약물요법
수술
세계의 비용종 치료 시장 : 경로별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
구강
비강
기타 경로
세계의 비용종 치료 시장 : 배포처별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
병원 약국
소매 약국
온라인 약국
세계의 비용종 치료 시장 : 세분화 약물 치료의 유형, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
코르티코스테로이드
생물학적 제형
항히스타민제
생리식염수 코 세정제
세계의 비용종 치료 시장 : 세분화 수술의 유형, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
기능적 내시경하 부비강 수술(FESS)
폴립 절제술
내시경하 부비강 수술
풍선 부비강 확장술
부비동 재수술
제7장 지역별/국가별 분석
세계의 비용종 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
세계의 비용종 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029F, 2034F)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
비용종 치료 시장 : 경쟁 구도
비용종 치료 시장 : 기업 프로파일
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Teva Pharmaceutical Industries Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca plc
Bayer AG
Boehringer Ingelheim International GmbH
Cipla Ltd.
Circassia Pharmaceuticals plc
Dr. Reddy's Laboratories Ltd.
Genentech Inc.
Glenmark Pharmaceuticals Ltd.
Johnson & Johnson Services Inc.
Lupin Limited
Meda AB
Novartis AG
Optinose US Inc.
Orion Corporation
Pfizer Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
비용종 치료 시장(2029년) : 새로운 기회를 제공하는 국가
비용종 치료 시장(2029년) : 새로운 기회를 제공하는 부문
비용종 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Nasal polyps are soft, painless, noncancerous growths on the lining of nasal passages or sinuses. They often dangle like grapes or teardrops and are associated with conditions such as asthma, persistent infections, allergies, medication sensitivity, and other immunological disorders.
The nasal polyps treatment market involves the sales of treatments used for nasal polyps. These treatments aim to shrink or repair nasal polyps. Nasal polyps can have connections to various health issues, including asthma, persistent infections, allergies, medication sensitivity, and other immunological disorders. The market includes entities such as organizations, sole traders, and partnerships that provide products or services related to the treatment of nasal polyps.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The nasal polyps treatment market research report is one of a series of new reports from The Business Research Company that provides nasal polyps treatment market statistics, including nasal polyps treatment industry global market size, regional shares, competitors with a nasal polyps treatment market share, detailed nasal polyps treatment market segments, market trends and opportunities, and any further data you may need to thrive in the nasal polyps treatment industry. This nasal polyps treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nasal polyps treatment market size has grown strongly in recent years. It will grow from $5.27 billion in 2024 to $5.68 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to surgical procedures, steroid medications, allergic rhinitis, chronic sinusitis, environmental factors.
The nasal polyps treatment market size is expected to see strong growth in the next few years. It will grow to $8.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to drug development, personalized medicine, telehealth services, patient-centric care, regulatory approvals. Major trends in the forecast period include diagnostic technologies, medical advancements, biologic therapies, immunotherapies, collaborative research.
The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may hinder chronic rhinosinusitis care by increasing costs for biologic therapies and endoscopic sinus surgery instruments sourced from Switzerland and South Korea, resulting in delayed interventions and higher Ear, Nose, and Throat(ENT) procedure costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
Increasing healthcare expenditure is anticipated to propel the growth of the nasal polyps treatment market. Healthcare expenditure refers to the total financial resources utilized by individuals, governments, and organizations within a healthcare system to cover costs associated with medical services, treatments, medications, and healthcare infrastructure. As healthcare budgets grow, more resources are likely to be allocated for the diagnosis, management, and treatment of nasal polyps. This financial investment can enhance patient access to advanced therapies, innovative treatment options, and increased research and development, ultimately driving market expansion. For example, in December 2023, data from the Centers for Medicare & Medicaid Services, a US-based federal agency, revealed that U.S. healthcare spending rose by 4.1%, reaching $4.5 trillion in 2022, surpassing the 3.2% growth recorded in 2021. Thus, the rising healthcare expenditure is fostering growth in the nasal polyps treatment market.
The increasing aging population is projected to drive the growth of the nasal polyps treatment market in the coming years. An aging population refers to a demographic shift marked by a higher percentage of elderly individuals (typically aged 65 and older) compared to younger age groups within a given population. As people age, they become more prone to nasal polyps, which are frequently seen in older adults. For example, in October 2024, data published by the World Health Organization, a United Nations agency based in Switzerland, indicated that the global population aged 60 and over is expected to grow from 1 billion in 2020 to 1.4 billion by 2030 and double to 2.1 billion by 2050, representing one in six people worldwide. Consequently, the rising aging population is set to boost the nasal polyps treatment market.
New product innovation is a significant trend gaining traction in the treatment of nasal polyps. Leading companies in the nasal polyps treatment market are emphasizing new product developments to enhance their market presence. For example, in September 2024, AstraZeneca, a UK-based pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) had approved Fasenra (benralizumab). This drug represents a considerable advancement in treating eosinophilic granulomatosis with polyangiitis (EGPA), achieving nearly 60% remission among patients and allowing 41% to completely discontinue oral corticosteroids, thereby minimizing long-term side effects associated with steroids. This approval broadens treatment options for approximately 15,000 patients in the U.S. with EGPA, a condition frequently linked to debilitating nasal and sinus symptoms, further highlighting the demand for effective therapies in managing eosinophilic diseases.
Major companies in the Nasal Polyps Treatment market are actively pursuing Food and Drug Administration (FDA) approvals to introduce new therapies. FDA approvals refer to the regulatory procedures through which the U.S. FDA assesses and authorizes the marketing and distribution of drugs, medical devices, and food products, ensuring their safety and effectiveness for public use. For example, in September 2024, Regeneron Pharmaceuticals, Inc., a U.S.-based biopharmaceutical company, along with Sanofi SA, a pharmaceutical and healthcare company based in France, announced the approval of Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) by the U.S. Food and Drug Administration (FDA). This approval designates it as the first and only biologic treatment specifically indicated for this age group. It addresses the unmet medical needs of around 9,000 adolescents in the U.S. suffering from CRSwNP, providing a new option that alleviates symptoms, decreases nasal polyp recurrence, and improves overall quality of life.
In May 2022, Medtronic plc, a medical device company based in Ireland, acquired Intersect ENT for $1.1 billion. This acquisition is designed to enhance its ear, nose, and throat (ENT) portfolio by integrating innovative bioabsorbable steroid-eluting sinus implants, which aim to improve post-operative outcomes and meet the treatment needs of patients with chronic rhinosinusitis and nasal polyps. Intersect ENT is a U.S.-based medical technology firm that produces drug delivery devices for ear, nose, and throat (ENT) applications, including treatments for nasal polyps.
Major companies operating in the nasal polyps treatment market include Sanofi SA, GlaxoSmithKline plc, F. Hoffmann La Roche AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Cipla Ltd., Circassia Pharmaceuticals plc, Dr. Reddy's Laboratories Ltd., Genentech Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Lupin Limited, Meda AB, Novartis AG, Optinose US Inc., Orion Corporation, Pfizer Inc., Regeneron Ireland DAC, Regeneron Pharmaceuticals Inc., Sandoz International GmbH, Stallergenes Greer plc, Sun Pharmaceutical Industries Ltd., Vectura Group plc, Zydus Cadila Ltd.
North America was the largest region in the nasal polyps treatment market in 2024 Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal polyps treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the nasal polyps treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
The nasal polyps treatment market includes revenues earned by entities by nasal corticosteroids, oral and injectable corticosteroids, and other medications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nasal Polyps Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nasal polyps treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for nasal polyps treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nasal polyps treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Pharmacological Therapies; Surgeries
2) By Route: Oral; Nasal; Other Routes
3) By Distribution: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Pharmacological Therapies: Corticosteroids; Biologics; Antihistamines; Saline Nasal Irrigation
2) By Surgeries: Functional Endoscopic Sinus Surgery (FESS); Polypectomy; Endoscopic Sinus Surgery; Balloon Sinus Dilation; Revision Sinus Surgery
Companies Mentioned: Sanofi SA; GlaxoSmithKline plc; F. Hoffmann La Roche AG; Merck & Co. Inc.; Teva Pharmaceutical Industries Ltd.; AstraZeneca plc; Bayer AG; Boehringer Ingelheim International GmbH; Cipla Ltd.; Circassia Pharmaceuticals plc; Dr. Reddy's Laboratories Ltd.; Genentech Inc.; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services Inc.; Lupin Limited; Meda AB; Novartis AG; Optinose US Inc.; Orion Corporation; Pfizer Inc.; Regeneron Ireland DAC; Regeneron Pharmaceuticals Inc.; Sandoz International GmbH; Stallergenes Greer plc; Sun Pharmaceutical Industries Ltd.; Vectura Group plc; Zydus Cadila Ltd.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Nasal Polyps Treatment Market Characteristics
3. Nasal Polyps Treatment Market Trends And Strategies
4. Nasal Polyps Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Nasal Polyps Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Nasal Polyps Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Nasal Polyps Treatment Market Growth Rate Analysis
5.4. Global Nasal Polyps Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Nasal Polyps Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Nasal Polyps Treatment Total Addressable Market (TAM)
6. Nasal Polyps Treatment Market Segmentation
6.1. Global Nasal Polyps Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmacological Therapies
Surgeries
6.2. Global Nasal Polyps Treatment Market, Segmentation By Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Nasal
Other Routes
6.3. Global Nasal Polyps Treatment Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Nasal Polyps Treatment Market, Sub-Segmentation Of Pharmacological Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Corticosteroids
Biologics
Antihistamines
Saline Nasal Irrigation
6.5. Global Nasal Polyps Treatment Market, Sub-Segmentation Of Surgeries, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Functional Endoscopic Sinus Surgery (FESS)
Polypectomy
Endoscopic Sinus Surgery
Balloon Sinus Dilation
Revision Sinus Surgery
7. Nasal Polyps Treatment Market Regional And Country Analysis
7.1. Global Nasal Polyps Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Nasal Polyps Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
